AmCad BioMed Corporation (TPEX:4188)

Market Cap	791.66M -39.5%
Revenue (ttm)	30.44M -42.7%
Net Income	-55.72M
EPS	-0.88
Shares Out	63.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,474
Average Volume	41,892
Open	12.50
Previous Close	12.60
Day's Range	12.25 - 12.55
52-Week Range	12.30 - 19.55
Beta	0.34
RSI	26.40
Earnings Date	May 8, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 34
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4188

Financial Performance

In 2025, AmCad BioMed's revenue was 30.44 million, a decrease of -42.69% compared to the previous year's 53.11 million. Losses were -55.72 million, 10.2% more than in 2024.